What drove GNRO.PA stock higher today?

The rise was driven by renewed investor interest in GeNeuro’s clinical pipeline and speculative buying ahead of upcoming milestones. Volume of 226,998 shares exceeded the 178,139 average, signalling short-term demand rather than a confirmed fundamental shift.

What is Meyka AI’s view on GNRO.PA stock?

Meyka AI rates GNRO.PA with a score out of 100 at 65.27 (Grade B | HOLD). The assessment balances clinical potential against weak cash metrics and dilution risk. This rating is informational and not investment advice.

What price targets or forecasts exist for GNRO.PA stock?

Meyka AI's forecast model projects a monthly level of €0.06 and a quarterly scenario at €0.64. A conservative 12‑month analyst-style target of €0.05 would imply about 73.61% upside from €0.0288. Forecasts are model-based, not guarantees.

What are the main risks for GNRO.PA investors?

Major risks include negative EPS (‑0.59), low liquidity, potential share dilution, and binary clinical outcomes. Absent positive trial news or funding, the stock can remain volatile and prone to sharp declines.

EU Stocks

GeNeuro (GNRO.PA) rises 9.92% to €0.0288 at close: catalysts to watch

ByDanny Kontos January 8, 2026January 8, 2026

GeNeuro SA (GNRO.PA) closed up 9.92% on 08 Jan 2026, ending the session at €0.0288 on EURONEXT in Europe. GNRO.PA stock led small-cap gainers on heavier-than-average volume of 226,998 shares versus an average of 178,139. The move pushed the stock back above the day low of €0.0274 and still far below the year high of €0.28. Traders flagged clinical-program updates and short-term technical support as reasons for the pop. Below we break down drivers, valuation, technicals, our Meyka AI grade and model-based forecasts to help investors make sense of today’s top gainer